Faron Pharmaceuticals Ltd.and Rentschler Biotechnologie GmbH announced that they have signed a manufacturing and supply agreement for the Faron product FP-1201 that is also known as Traumakine. The active pharmaceutical ingredient of the FP-1201 is recombinant human interferon beta-1a (IFN-beta 1a) that was first produced by Rentschler already in the late 1980's. According to the agreement Rentschler will become the sole global manufacturer of IFN-beta 1a for Faron and also manufacture

Faron's proprietary bulk drug product - Traumakine is formulated so that it is stable at room temperature and readily available for critical care doctors at intensive treatment units. Traumakine is meant to prevent vascular leakage in patients with Acute Lung Injuries (ALI) and its more severe form ARDS. This prevention is critical to sustain respiratory function in ALI/ARDS patients. Financial details of the agreement were not disclosed.